Rituximab Administration Guidelines

Standard Dosing Regimens

The standard dose of rituximab is 375 mg/m² body surface area, administered as an intravenous infusion, typically given once weekly for 4 consecutive weeks, though the specific regimen varies by indication 1, 2
For B-cell non-Hodgkin's lymphoma, the American Society of Clinical Oncology recommends administering 375 mg/m² IV once weekly for 4 weeks as the standard monotherapy regimen 3, 4, 5
For diffuse large B-cell lymphoma in combination with CHOP, the European Society for Medical Oncology suggests giving 375 mg/m² IV on day 1 of each chemotherapy cycle, administered 1 day before chemotherapy 1, 2
For Burkitt lymphoma/leukemia, eight infusions of rituximab at 375 mg/m² are recommended as the standard when combined with intensive chemotherapy, according to the National Comprehensive Cancer Network 1, 2
For CD20-positive B-cell acute lymphoblastic leukemia, the American Society of Hematology recommends administering eight doses of rituximab 375 mg/m² during induction and consolidation cycles, or 16-18 infusions depending on the protocol 1, 2
For immune thrombocytopenia (ITP), the American Society of Hematology suggests using 375 mg/m² IV once weekly for 4 consecutive weeks, though lower doses may be sufficient 6

For certain autoimmune conditions, a fixed-dose regimen of 1000 mg IV on day 1 and repeated on day 15 is an acceptable alternative to the body surface area-based dosing, according to the American College of Rheumatology 7, 8

Premedication with antipyretic and antihistamine is essential before each infusion to reduce infusion reactions, as recommended by the American Society of Clinical Oncology 8

Infusion reactions occur in up to 77% of patients during the first infusion, with decreasing frequency in subsequent infusions, according to the American Society of Clinical Oncology 8
For Grade 1/2 reactions, the American Society of Clinical Oncology recommends slowing or temporarily stopping the infusion and providing symptomatic treatment 8
For Grade 3/4 reactions, the American Society of Clinical Oncology suggests stopping the infusion immediately and providing aggressive symptomatic treatment 8

Baseline immunoglobulin levels (IgG, IgM, IgA) should be obtained to monitor for hypogammaglobulinemia risk, as recommended by the American College of Rheumatology 7, 8
Hepatitis B and C antibody screening should be performed due to risk of viral reactivation, according to the Centers for Disease Control and Prevention 7, 8
Latent tuberculosis screening should be performed prior to administration, as recommended by the American Thoracic Society 7, 8
Complete blood count with differential should be performed at baseline and at 2-4 month intervals during treatment, according to the American Society of Clinical Oncology 7, 8

Avoid rituximab in patients with active hepatitis B infection due to risk of reactivation, as recommended by the Centers for Disease Control and Prevention 7
Progressive multifocal leukoencephalopathy is a rare but potentially fatal complication; use caution in immunosuppressed patients, according to the American Society of Clinical Oncology 7, 8
Hypogammaglobulinemia risk increases with multiple courses, particularly affecting patients who receive repeated treatments; monitor serum immunoglobulin levels periodically, as recommended by the American Journal of Hematology 6

Standard lymphoma protocols typically last 4 weeks for monotherapy, according to the National Comprehensive Cancer Network 3, 4, 5
Extended lymphoma protocols may last from 1 to 8 weeks in clinical studies, with most patients receiving 4 weeks, as reported in the journal Blood 3, 4, 5
Combination with chemotherapy typically involves one dose per chemotherapy cycle over 6-8 cycles, according to the European Society for Medical Oncology 1, 2